報價延遲最少15分鐘:2025/08/25 16:58 EDT
盤後時段
|
||||
|
91.55 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
91.55
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.61/0.05
|
|
企業價值
5.50B
|
| 資產負債 |
|
每股賬面淨值
13.34
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
383.48M
|
|
每股收益
5.29
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/08/25 16:58 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite. |
